CA2814385C - Biomarker for alzheimer's disease or mild cognitive impairment - Google Patents
Biomarker for alzheimer's disease or mild cognitive impairment Download PDFInfo
- Publication number
- CA2814385C CA2814385C CA2814385A CA2814385A CA2814385C CA 2814385 C CA2814385 C CA 2814385C CA 2814385 A CA2814385 A CA 2814385A CA 2814385 A CA2814385 A CA 2814385A CA 2814385 C CA2814385 C CA 2814385C
- Authority
- CA
- Canada
- Prior art keywords
- level
- blood
- desmosterol
- candidate
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 151
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 148
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 139
- 239000000090 biomarker Substances 0.000 title abstract description 22
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 claims abstract description 224
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 claims abstract description 224
- 238000000034 method Methods 0.000 claims abstract description 112
- 102000004878 Gelsolin Human genes 0.000 claims abstract description 107
- 108090001064 Gelsolin Proteins 0.000 claims abstract description 107
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 56
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 56
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims 4
- 239000008280 blood Substances 0.000 abstract description 273
- 239000003814 drug Substances 0.000 abstract description 57
- 229940124597 therapeutic agent Drugs 0.000 abstract description 49
- 230000000694 effects Effects 0.000 abstract description 29
- 238000003745 diagnosis Methods 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 description 272
- 238000005259 measurement Methods 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000001149 cognitive effect Effects 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 230000008901 benefit Effects 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- HVYWMOMLDIMFJA-IFAPJKRJSA-N Cholesterol_d7 Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@@]1(C)CC2 HVYWMOMLDIMFJA-IFAPJKRJSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 241001279686 Allium moly Species 0.000 description 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 208000029755 cholesterol metabolism disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/203332—Hydroxyl containing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010235203 | 2010-10-20 | ||
| JP2010-235203 | 2010-10-20 | ||
| US201061424885P | 2010-12-20 | 2010-12-20 | |
| JP2010282938 | 2010-12-20 | ||
| JP2010-282938 | 2010-12-20 | ||
| US61/424885 | 2010-12-20 | ||
| PCT/JP2011/064487 WO2012053255A1 (ja) | 2010-10-20 | 2011-06-23 | アルツハイマー病又は軽度認知症のバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2814385A1 CA2814385A1 (en) | 2012-04-26 |
| CA2814385C true CA2814385C (en) | 2017-10-24 |
Family
ID=45974981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2814385A Expired - Fee Related CA2814385C (en) | 2010-10-20 | 2011-06-23 | Biomarker for alzheimer's disease or mild cognitive impairment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9581604B2 (https=) |
| EP (1) | EP2631646B1 (https=) |
| JP (1) | JP5695075B2 (https=) |
| AU (1) | AU2011319319B2 (https=) |
| BR (1) | BR112013009592A2 (https=) |
| CA (1) | CA2814385C (https=) |
| IN (1) | IN2013CN02996A (https=) |
| NZ (1) | NZ609324A (https=) |
| RU (1) | RU2563987C2 (https=) |
| WO (1) | WO2012053255A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212084D0 (en) * | 2012-07-06 | 2012-08-22 | Randox Lab Ltd | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment |
| EP3267200A4 (en) * | 2015-03-06 | 2018-08-22 | Niigata University | Biomarker of dementia with lewy bodies |
| ES2657414T3 (es) * | 2015-11-20 | 2018-03-05 | Geroa Diagnostics, S.L | Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer |
| CN114410774A (zh) * | 2022-02-17 | 2022-04-29 | 杭州怡健医疗科技有限公司 | 一种应用于阿尔茨海默氏症的患病风险评估方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088811A2 (en) * | 2002-04-16 | 2003-10-30 | The Brigham And Women's Hospital, Inc. | Gelsolin as a prognostic marker of artherosclerotic diseases |
| JPWO2007097461A1 (ja) * | 2006-02-27 | 2009-07-16 | 国立大学法人 熊本大学 | Ｃ型肝炎治療用抗体 |
| US7645748B2 (en) * | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| RU2356058C2 (ru) * | 2006-11-27 | 2009-05-20 | Александр Васильевич Мальцев | Способ диагностики амилоидоза при болезни альцгеймера и комплект средств для его осуществления |
-
2011
- 2011-06-23 CA CA2814385A patent/CA2814385C/en not_active Expired - Fee Related
- 2011-06-23 BR BR112013009592A patent/BR112013009592A2/pt not_active Application Discontinuation
- 2011-06-23 AU AU2011319319A patent/AU2011319319B2/en not_active Ceased
- 2011-06-23 US US13/880,475 patent/US9581604B2/en not_active Expired - Fee Related
- 2011-06-23 JP JP2012539625A patent/JP5695075B2/ja not_active Expired - Fee Related
- 2011-06-23 IN IN2996CHN2013 patent/IN2013CN02996A/en unknown
- 2011-06-23 RU RU2013122853/15A patent/RU2563987C2/ru not_active IP Right Cessation
- 2011-06-23 WO PCT/JP2011/064487 patent/WO2012053255A1/ja not_active Ceased
- 2011-06-23 EP EP11834097.5A patent/EP2631646B1/en active Active
- 2011-06-23 NZ NZ609324A patent/NZ609324A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012053255A1 (ja) | 2012-04-26 |
| AU2011319319A1 (en) | 2013-05-02 |
| NZ609324A (en) | 2014-09-26 |
| EP2631646B1 (en) | 2016-10-19 |
| US20130266589A1 (en) | 2013-10-10 |
| BR112013009592A2 (pt) | 2016-07-12 |
| US9581604B2 (en) | 2017-02-28 |
| JP5695075B2 (ja) | 2015-04-01 |
| RU2013122853A (ru) | 2014-11-27 |
| CA2814385A1 (en) | 2012-04-26 |
| EP2631646A1 (en) | 2013-08-28 |
| IN2013CN02996A (https=) | 2015-08-14 |
| EP2631646A4 (en) | 2014-05-07 |
| AU2011319319B2 (en) | 2015-07-30 |
| RU2563987C2 (ru) | 2015-09-27 |
| JPWO2012053255A1 (ja) | 2014-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Csősz et al. | Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy | |
| Pannee et al. | The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease | |
| Sjödin et al. | Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease | |
| Korecka et al. | Qualification of a surrogate matrix-based absolute quantification method for amyloid-β42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry | |
| JP6954839B2 (ja) | アルツハイマー病の診断及び治療のための材料及び方法 | |
| Begcevic et al. | Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains | |
| WO2022213746A1 (zh) | 用于诊断和治疗脑白质病变的方法及其应用 | |
| JP2013512444A (ja) | 多発性硬化症を診断するための手段及び方法 | |
| CA2814385C (en) | Biomarker for alzheimer's disease or mild cognitive impairment | |
| WO2022206264A1 (zh) | 用于诊断和治疗脑白质病变的方法及其应用 | |
| EP3242134A1 (en) | Assay for the diagnosis of a neurological disease | |
| KR20140002712A (ko) | 당뇨병 예측 수단 및 방법 | |
| EP3427064A1 (en) | Biomarker for the diagnosis of pulmonary hypertension (ph) | |
| Lin et al. | An UHPLC–MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction | |
| US20180024150A1 (en) | Biomarker of dementia with lewy bodies | |
| KR101946884B1 (ko) | 대사체 분석을 이용한 베체트병의 진단방법 | |
| JP2016526167A (ja) | アルツハイマー病に関する物質と方法 | |
| Zhong et al. | A strategy for discovery and verification of candidate biomarkers in cerebrospinal fluid of preclinical Alzheimer’s disease | |
| Hansson et al. | Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease | |
| WO2018007422A1 (en) | Identification of human non-alcoholic fatty liver disease (nafld) subtypes | |
| JP2020064051A (ja) | 神経変性疾患の診断用ペプチドマーカー | |
| US11899027B2 (en) | Diagnostic methods based on lipid profiles | |
| WO2013038739A1 (ja) | 肺癌マーカー補体Ｃ３ｄｇ分子及び肺癌マーカーの分析方法 | |
| KR102177280B1 (ko) | 호모시스테인 설핀산 또는 시스테인산을 포함하는 급성심근경색 진단용 바이오마커 조성물 | |
| EP4370931B1 (en) | Biomarkers for alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140626 |
|
| MKLA | Lapsed |
Effective date: 20200831 |